Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Associate Partners:

  • Kotak Mutual Fund
  • Pharmeasy
  • Indiabulls
  • SBI

Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Technology Partner

Dell Technologies

Associate Partners

Kotak Mutual Fund
Pharmeasy
Indiabulls
SBI
you are here: HomeNewsBiocon
management interviews
Jump to
71 Results Found
  • EXCLUSIVE: Kiran Mazumdar-Shaw asks govt to let companies use CSR funds to vaccinate employees Nov 18, 2020 05:51 PM IST

    EXCLUSIVE: Kiran Mazumdar-Shaw asks govt to let companies use CSR funds to vaccinate employees

    Her suggestion could possibly lessen the burden on the government, which is grappling to get a measure of the exact cost to vaccinate the entire country and getting the logistics and supply chain in place to administer the vaccine. It is estimated that it could cost a minimum of Rs 50,000 crore to vaccinate the country.

  • Biocon confident of meeting $200-million revenue guidance target for biologics segment Oct 27, 2018 08:00 AM IST

    Biocon confident of meeting $200-million revenue guidance target for biologics segment

    “We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.

  • Mechanics of Modicare: The health scheme fine print Feb 12, 2018 09:05 PM IST

    Mechanics of Modicare: The health scheme fine print

    The government is calling it the "world's largest government healthcare scheme"--- the showpiece announcement of the Budget 2018 was a healthcare assurance scheme.

  • Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon Jan 25, 2018 12:57 PM IST

    Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon

    We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.

  • Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl Jan 24, 2018 02:19 PM IST

    Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

    EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.

  • Partnership with Sandoz is for the future wave of biosimilars: Biocon Jan 19, 2018 12:28 PM IST

    Partnership with Sandoz is for the future wave of biosimilars: Biocon

    The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.

  • TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study Dec 08, 2017 12:19 PM IST

    TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

    Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study

  • Trastuzumab approval is a milestone: Biocon Dec 04, 2017 11:40 AM IST

    Trastuzumab approval is a milestone: Biocon

    In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said Trastuzumab approval is a huge milestone. It has been under development for seven years.

  • EMA communication with regards to Trastuzumab does not mean an approval: Biocon Dec 01, 2017 09:50 AM IST

    EMA communication with regards to Trastuzumab does not mean an approval: Biocon

    European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke at length about the same.

  • Optimistic about entry into generics market; hoping for better returns in H2: Biocon Oct 27, 2017 12:53 PM IST

    Optimistic about entry into generics market; hoping for better returns in H2: Biocon

    In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.

  • It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang Oct 10, 2017 11:04 AM IST

    It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang

    In an interview to CNBC-TV18, Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities shared his views and readings on the news as well as on Biocon stock.

  • Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO Oct 07, 2017 02:55 PM IST

    Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

    Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.

  • Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon Sep 08, 2017 09:30 AM IST

    Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon

    Small booster for Biocon as they have received a certificate of good manufacturing practices (GMP) compliance from the European regulator for its insulin manufacturing facility in Malaysia.

  • Biocon seeks withdrawal of application for two biosimilars under European drug regulator review Aug 16, 2017 03:14 PM IST

    Biocon seeks withdrawal of application for two biosimilars under European drug regulator review

    “The request for withdrawal of the dossiers and re-submission is part of EMA procedural requirements linked to this re-inspection and will be considered by the EMA’s Committee for Medicinal Products of Human Use (CHMP),” the company said.

  • Will try & ask for re-inspection at the earliest, says Biocon Jul 10, 2017 10:27 AM IST

    Will try & ask for re-inspection at the earliest, says Biocon

    There appears to be a setback for Biocon as its biosimilars program hits a roadblock in Europe -- the drug products unit inspection done in March has not received the GMP certificate by the French regulator. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke about the latest happenings in the company.

  • Countdown to GST: Find out how India Inc views its impacts Jun 11, 2017 06:05 PM IST

    Countdown to GST: Find out how India Inc views its impacts

    Watch the interview of Kiran Mazumdar-Shaw, CMD of Biocon, Rakesh Biyani, Joint MD at Future Retail, Gnanesh Gala of Navneet Education, Harsh Mariwala of Marico, Bharat Madan, Group CFO at Escorts and KU Subbiah, CFO, VST Tillers Tractors in which they shared their views on how goods and services tax (GST) will impact businesses across the country.

  • EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A Apr 28, 2017 07:56 PM IST

    EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A

    Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.

  • To cut healthcare costs, US must partner India: Biocon's Shaw Mar 03, 2017 11:26 AM IST

    To cut healthcare costs, US must partner India: Biocon's Shaw

    Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.

  • Biocon to see inspections by USFDA & EMA in April-May: Sources Mar 02, 2017 01:45 PM IST

    Biocon to see inspections by USFDA & EMA in April-May: Sources

    Biotech company, Biocon will see two crucial inspections later this month and in early April. Company‘s manufacturing sites will come up for inspections by the European medicines agency later this month and next will be an inspection by the US FDA.

  • Biocon chief sees anti-cancer biosimilar launch in FY19 Feb 17, 2017 09:51 AM IST

    Biocon chief sees anti-cancer biosimilar launch in FY19

    Biocon Thursday announced the US Food and Drug Administration has accepted Mylan‘s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."

  • Biocon well-poised to be a frontrunner in biosimilars: MD Jan 25, 2017 11:02 AM IST

    Biocon well-poised to be a frontrunner in biosimilars: MD

    Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.

  • I don't see Trump's views affecting Indian drug cos: Biocon CMD Jan 12, 2017 08:43 AM IST

    I don't see Trump's views affecting Indian drug cos: Biocon CMD

    Following US president-elect Donald Trump‘s explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.

  • Speciality offers better returns, says Biocon Chief Dec 22, 2016 12:02 PM IST

    Speciality offers better returns, says Biocon Chief

    Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.

  • Demonetisation has impacted Indian sales, not exports: Biocon Dec 06, 2016 12:52 PM IST

    Demonetisation has impacted Indian sales, not exports: Biocon

    Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.

  • Half of US stunned, other half exhilarated with Trump win: Shaw Nov 09, 2016 09:49 PM IST

    Half of US stunned, other half exhilarated with Trump win: Shaw

    In an interview with CNCB-TV18, Kiran Mazumdar Shaw, CMD of Biocon said that people worldwide are losing confidence in entrenched political systems and many feel marginalized and neglected from the economic developments that happen.

Sections
ISO 27001 - BSI Assurance Mark